BioCentury | Mar 27, 2021

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

EMA to review Padcev for urothelial cancerAstellas Pharma Inc. (Tokyo:4503) and Seagen Inc. (NASDAQ:SGEN) said EMA accepted an MAA for Padcev enfortumab vedotin, an antibody-drug conjugate (ADC) targeting PRR4, to treat locally advanced or metastatic urothelial...
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Metalloprotease MYSM1 identified as protective factor in lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Promoting the expression of the metalloprotease MYSM1 could treat systemic lupus erythematous (SLE). MYSM1 mRNA and protein levels were lower in peripheral blood mononuclear cells (PBMCs) from 14 SLE...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis; herpes simplex virus (HSV) Inhibiting CXCL1 or its receptor, CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1 encephalitis, systemic knockout of CXCR2 lowered disease scores, improved survival and reduced...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis Inhibiting the chemokine receptor CXCR3 or its ligand CXCL9 could treat osteoporosis. In a medaka fish model of RANKL-induced osteoporosis, two CXCR3 inhibitor tool compounds reduced mineralization defects including resorption...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

As Gilead continues to expand its manufacturing capabilities for Veklury, the company has moved a step closer to gaining full approval of the therapy in the U.S. for COVID-19. The company announced its NDA submission for...
BioCentury | Apr 22, 2020
Product Development

FDA clears LabCorp’s COVID-19 home collection kits as Congress looks to bolster testing with $25B

LabCorp became the first diagnostic company to have an at-home collection kit for COVID-19 authorized by FDA, a month after the agency cleared its lab PCR test for the novel coronavirus. FDA also gave a...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Jan 18, 2020
Financial News

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border development strategy. The...
Items per page:
1 - 10 of 306